人工呼吸器関連肺炎(Ventilator Associated Pneumonia (VAP))の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ventilator Associated Pneumonia (VAP) Overview 8
Therapeutics Development 9
Pipeline Products for Ventilator Associated Pneumonia (VAP) – Overview 9
Pipeline Products for Ventilator Associated Pneumonia (VAP) – Comparative Analysis 10
Ventilator Associated Pneumonia (VAP) – Therapeutics under Development by Companies 11
Ventilator Associated Pneumonia (VAP) – Therapeutics under Investigation by Universities/Institutes 13
Ventilator Associated Pneumonia (VAP) – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Ventilator Associated Pneumonia (VAP) – Products under Development by Companies 18
Ventilator Associated Pneumonia (VAP) – Products under Investigation by Universities/Institutes 19
Ventilator Associated Pneumonia (VAP) – Companies Involved in Therapeutics Development 20
Adenium Biotech ApS 20
AstraZeneca PLC 21
Cardeas Pharma Corp. 22
Cubist Pharmaceuticals, Inc. 23
Dong-A Socio Group 24
F. Hoffmann-La Roche Ltd. 25
KaloBios Pharmaceuticals, Inc. 26
Meiji Seika Pharma Co., Ltd. 27
Nabriva Therapeutics AG 28
Paratek Pharmaceuticals, Inc. 29
Savara Inc. 30
Serendex Pharmaceuticals A/S 31
Tetraphase Pharmaceuticals Inc. 32
Ventilator Associated Pneumonia (VAP) – Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
(amikacin + fosfomycin) – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(ceftazidime + avibactam) – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(ceftolozane sulfate + tazobactam sodium) – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
AA-139 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
arbekacin – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BC-3781 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
eravacycline – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
fosfomycin – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
KB-001A – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MEDI-4893 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
molgramostim – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Nu-2 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
pseudomonas aeruginosa vaccine – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
pseudomonas and VAP conjugate vaccine – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Qn-2251 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
RG-7929 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecules for Infectious Diseases – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
tedizolid phosphate – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
vancomycin hydrochloride – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Ventilator Associated Pneumonia (VAP) – Recent Pipeline Updates 73
Ventilator Associated Pneumonia (VAP) – Dormant Projects 93
Ventilator Associated Pneumonia (VAP) – Discontinued Products 94
Ventilator Associated Pneumonia (VAP) – Product Development Milestones 95
Featured News & Press Releases 95
May 07, 2013: Cubist’s Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 97
Disclaimer 97